Isuprel

Country: New Zealand

Bahasa: Inggeris

Sumber: Medsafe (Medicines Safety Authority)

Bahan aktif:

Isoprenaline hydrochloride 0.2 mg/mL;  ; Isoprenaline hydrochloride 200 µg/mL

Boleh didapati daripada:

Pfizer New Zealand Limited

INN (Nama Antarabangsa):

Isoprenaline hydrochloride 0.2 mg/mL

Dos:

0.2 mg/mL

Borang farmaseutikal:

Solution for injection

Komposisi:

Active: Isoprenaline hydrochloride 0.2 mg/mL   Excipient: Lactic acid Sodium chloride Sodium lactate Sodium metabisulfite Water for injection Active: Isoprenaline hydrochloride 200 µg/mL Excipient: Citric acid Disodium edetate Hydrochloric acid Nitrogen Sodium chloride Sodium citrate dihydrate Sodium hydroxide Water for injection

Unit dalam pakej:

Ampoule, glass, 25 x 1mL, 25 mL

Kelas:

Prescription

Jenis preskripsi:

Prescription

Dikeluarkan oleh:

Hospira Boulder, Inc.

Tanda-tanda terapeutik:

Isuprel is indicated for: 1. Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. 2. Serious episodes of heart block and Adams-Stokes attack (except when caused by ventricular tachycardia of fibrillation). 3. Use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available. 4. Bronchospasm occurring during anaesthesia. 5. As an adjunct to fluid and electrolyte replacement therapy and the use of other medicines and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

Ringkasan produk:

Package - Contents - Shelf Life: Ampoule, glass, 25 x 1mL (formulation to 04 Apirl 2014) - 25 mL - 18 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Ampoule, glass, 25 x 1mL - 25 mL - 18 months from date of manufacture stored at or below 25°C protect from light - Ampoule, glass, 10 x 5mL (formulation to 04 Apirl 2014) - 50 mL - 18 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Ampoule, glass, 50 x 1mL (formulation to 04 April 2014) - 50 mL - 18 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Ampoule, glass, 10 x 5mL - 50 mL - 18 months from date of manufacture stored at or below 25°C protect from light

Tarikh kebenaran:

1969-12-31

Ciri produk

Data Sheet – New Zealand
Hospira 2.0
1
ISUPREL
™
_ _
NAME OF MEDICINE
Isoprenaline Hydrochloride 0.2mg/mL Injection
PRESENTATION
A colourless sterile solution of Isoprenaline hydrochloride in a 1mL
or 5mL glass ampoule. Each
mL of the sterile non pyrogenic 1:5000 solution contains 0.2mg of
Isoprenaline hydrochloride,
sodium citrate dihydrate, anhydrous citric acid, sodium chloride,
water for injection, and
hydrochloric acid or sodium hydroxide
(for pH adjustment).
_ _
_ _
USES
_ACTIONS _
Isoprenaline is a potent non selective beta-adrenergic agonist with
low affinity for alpha-
adrenergic receptors.
Isoprenaline acts primarily on the heart and on smooth muscle of
bronchi, skeletal muscle
vasculature and the gastrointestinal tract.
Isoprenaline increases cardiac output due to its positive inotropic
and chronotropic actions and
increasing venous return. With usual therapeutic doses, the increase
in cardiac output is
generally sufficient to maintain or increase systolic blood pressure.
Intravenous infusion of
isoprenaline also lowers peripheral vascular resistance. The diastolic
pressure, therefore, may be
expected to fall in normal individuals. Thus the mean pressure may be
reduced. The rate of
discharge of cardiac pacemakers is increased with isoprenaline.
Isoprenaline relaxes most smooth muscle, the most pronounced effect
being on bronchial and
gastrointestinal smooth muscle. It produces marked relaxation in the
smaller bronchi and may
even dilate the trachea and main bronchi past the resting diameter.
In man, isoprenaline causes less hyperglycaemia than does adrenaline.
Isoprenaline and
adrenaline are equally effective in stimulating the release of free
fatty acids and energy
production.
_ _
_PHARMACOKINETICS _
Isoprenaline is readily absorbed when given parenterally.
The half-life of isoprenaline hydrochloride is brief lasting only a
few minutes following intravenous
administration and up to 2 hours after subcutaneous administration.
Isoprenaline is metabolised
by catechol-o-methyl transferase primarily in